Dendritic cell-based vaccine targeting aspartate-ß-hydroxylas represents a promising therapeutic strategy for HCC.
Immunotherapy
; 11(16): 1399-1407, 2019 11.
Article
em En
| MEDLINE
| ID: mdl-31608722
ABSTRACT
Background:
Dendritic cells (DCs)-mediated immunotherapy has been considered as a promising antitumor method. Aspartate-ß-hydroxylase (AAH) is a potential immunotherapeutic target for hepatocellular carcinoma (HCC). Materials &methods:
C57BL/6 mice were immunized by AAH-DCs vaccine constructed ex vivo. Killing tumor cells effect of active T cells induced by AAH-DCs vaccine on HCC cells were measured in vitro and vivo. The underlying mechanism was preliminarily investigated.Results:
T cells response when activated by AAH-DCs vaccine showed a significant inhibition effect on HCC cells in vitro and in tumor-bearing mice models when compared with controls. Additionally, compared with the control group, increased expressions of Caspase8, Caspase 3 and Bax, and declined expression of Bcl-2 were observed in AAH-DCs vaccine group.Conclusion:
AAH-DCs vaccine could stimulate T cell responses against HCC, which was possibly achieved via pro-apoptosis mechanism.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Células Dendríticas
/
Imunoterapia Adotiva
/
Carcinoma Hepatocelular
/
Vacinas Anticâncer
/
Oxigenases de Função Mista
/
Neoplasias Hepáticas
Limite:
Animals
/
Female
/
Humans
Idioma:
En
Revista:
Immunotherapy
Assunto da revista:
ALERGIA E IMUNOLOGIA
/
TERAPEUTICA
Ano de publicação:
2019
Tipo de documento:
Article
País de afiliação:
China